Kymera Therapeutics Inc
$ 82.96
6.05%
11 Jun - close price
- Market Cap 6,435,011,000 USD
- Current Price $ 82.96
- High / Low $ 83.50 / 77.80
- Stock P/E N/A
- Book Value 18.73
- EPS -3.58
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -0.27 %
- 52 Week High 103.00
- 52 Week Low 36.65
About
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$118.55
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-26 | 2025-11-04 | 2025-08-11 | 2025-05-09 | 2025-02-27 | 2024-10-31 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.71 | -0.97 | -0.94 | -0.95 | -0.82 | -0.89 | -0.82 | -0.58 | -0.62 | -0.25 | -0.9 | -0.67 |
| Estimated EPS | -0.86 | -0.79 | -0.78 | -0.8 | -0.91 | -0.7882 | -0.84 | -0.66 | -0.72 | -0.4 | -0.7 | -0.74 |
| Surprise | 0.15 | -0.18 | -0.16 | -0.15 | 0.09 | -0.1018 | 0.02 | 0.08 | 0.1 | 0.15 | -0.2 | 0.07 |
| Surprise Percentage | 17.4419% | -22.7848% | -20.5128% | -18.75% | 9.8901% | -12.9155% | 2.381% | 12.1212% | 13.8889% | 37.5% | -28.5714% | 9.4595% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.76 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KYMR
2026-06-11 06:10:15
Kymera Therapeutics (KYMR) is gaining attention after a significant milestone payment from Sanofi due to patient dosing in the Phase I trial of KT-485, alongside new positive data for KT-579. Despite recent short-term share price fluctuations, the company has shown strong long-term returns, with many analysts seeing it as undervalued. Kymera's strategy for consistent pipeline expansion and a healthy cash runway position it for potential future growth, though high R&D spending and reliance on partners remain key considerations.
2026-06-10 14:39:16
Kymera Therapeutics (KYMR) shares rose by 4% after the company announced the initiation of patient dosing in a phase I study for KT-485, an IRAK4 protein degrader developed in partnership with Sanofi (SNY). This milestone triggered a $20 million payment from Sanofi to Kymera. The study will evaluate KT-485 in healthy volunteers and patients with hidradenitis suppurativa, assessing its safety, tolerability, and pharmacokinetics.
2026-06-10 13:39:16
This article identifies Kymera Therapeutics Inc. (NASDAQ:KYMR) as one of the top AI-driven biotech stocks to invest in. Brookline Capital Markets increased its target price for KYMR due to promising preclinical results for KT-579, a drug designed to treat inflammatory diseases by modulating multiple inflammatory pathways. Kymera Therapeutics is actively developing several small-molecule therapeutics targeting disease-causing proteins.
2026-06-10 06:39:16
Kymera Therapeutics initiated a Phase 1 trial for KT-485 (SAR447971), an IRAK4 degrader, triggering a $20 million payment from Sanofi. This second-generation molecule, described as more potent and selective than its predecessor, will be evaluated in healthy volunteers and hidradenitis suppurativa patients. The trial aims to determine if KT-485's mechanism of degrading IRAK4, rather than just inhibiting it, translates to a superior clinical effect in inflammatory skin disease.
2026-06-09 14:09:47
Kymera Therapeutics announced the dosing of the first participant in a Phase 1 clinical trial for KT-485 (SAR447971), an oral IRAK4 degrader, triggering a $20 million milestone payment from Sanofi. This second-generation degrader is being evaluated in healthy volunteers and hidradenitis suppurativa patients as part of a collaboration where Sanofi leads development, regulatory, and commercial efforts. Kymera is eligible for up to $975 million in additional milestones for this potential treatment for immuno-inflammatory conditions.
2026-06-09 11:09:47
Kymera Therapeutics announced the first participant has been dosed in a Phase 1 trial for KT-485, an oral IRAK4 degrader, triggering a $20 million milestone payment from Sanofi. This Sanofi-led study, which includes healthy adults and hidradenitis suppurativa patients, is part of a collaboration that could yield up to $975 million in potential milestones for Kymera. The trial will assess the drug's safety, tolerability, pharmacokinetics, and exploratory endpoints.
